{"id":"W3130005770","doi":"10.1007/s10549-021-06109-7","title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; National Institute for Health and Care Research; Pfizer","keywords":"Trastuzumab; Medicine; Enzalutamide; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Response Evaluation Criteria in Solid Tumors; Regimen; Adverse effect; Androgen receptor; Cancer; Clinical endpoint; Progressive disease; Phases of clinical research; Prostate cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005477953,0.0004346773,0.0006825412,0.0001719753,0.00015532,0.0004121698,0.0002497242,0.000270944,0.0008873335],"category_scores_gemma":[0.0006698511,0.0001764609,0.0003814251,0.0001805731,0.0002875167,0.0002674357,0.0001873721,0.0006589376,0.0001864363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005708144,"about_ca_system_score_gemma":0.0005604973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000489468,"about_ca_topic_score_gemma":0.001456065,"domain_scores_codex":[0.9997817,0.00009895879,0.00002115687,0.00003178928,0.00003928594,0.0000270269],"domain_scores_gemma":[0.9997786,0.00004269314,0.00008336891,0.00001095894,0.00001231917,0.00007211373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3791001,0.02747403,0.08519543,0.0008840224,0.001507783,0.0007851096,0.0003737903,0.004559852,0.08368606,0.0001495712,0.002472648,0.4138116],"study_design_scores_gemma":[0.1671726,0.5177001,0.2794937,0.0001311006,0.00113536,0.002365412,0.0001228973,0.005201862,0.01695724,0.0002551847,0.009417078,0.00004735709],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971795,0.001845035,0.0001197558,0.00007321043,0.00001065238,0.0001027966,0.00007310954,0.00001716129,0.0005787963],"genre_scores_gemma":[0.9986449,0.0004752657,0.0001943487,0.00008871827,0.00002487194,0.00006505187,0.0001807543,0.000002999097,0.000323038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008873335,"threshold_uncertainty_score":0.004141629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02784040980921412,"score_gpt":0.3571205290673999,"score_spread":0.3292801192581858,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}